Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial

{{article.zuoZheEn}}

PDF(449 KB)
PDF(449 KB)
Front. Med. ›› 2021, Vol. 15 ›› Issue (3) : 486-494. DOI: 10.1007/s11684-020-0824-3
RESEARCH ARTICLE

Tocilizumab in patients with moderate or severe COVID-19: a randomized, controlled, open-label, multicenter trial

  • {{article.zuoZheEn}}
Author information +
History +

Highlights

{{article.highlightEn}}

Abstract

{{article.abstractEn}}

Author summary

{{article.authorSummayEn}}

Graphical abstract

Keywords

Cite this article

Download citation ▾
{{article.zuoZheEn_L}}. {{article.titleEn}}. Front. Med., 2021, 15(3): 486‒494 https://doi.org/10.1007/s11684-020-0824-3

References

References

{{article.reference}}

RIGHTS & PERMISSIONS

{{article.copyright.year}} {{article.copyright.holder}}
PDF(449 KB)

Accesses

Citations

Detail

Sections
Recommended

/